文献速递炎症性肠病

炎症性肠病患者启动肿瘤坏死因子拮抗剂治疗的时间趋势:一项基于人群的分析

Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-02-24

该研究利用马尼托巴大学炎症性肠病流行病学数据库,识别2001年至2014年间接受抗肿瘤坏死因子(抗TNF)治疗的克罗恩病(CD)和溃疡性结肠炎(UC)患者,分析抗TNF使用率、启动时机及启动前免疫调节剂和糖皮质激素使用模式的变化。结果显示抗TNF使用增加,UC患者启动前累积糖皮质激素暴露随时间下降,但CD患者无显著下降,且CD患者联合免疫调节剂使用无变化。

要点

  • 2014年CD患者抗TNF累积暴露患病率为20.4%,UC为6.0%。
  • 2014年诊断后5年内抗TNF累积暴露发生率CD为23.4%,UC为7.8%。
  • 多数抗TNF使用者启动前存在糖皮质激素依赖(任意12个月内泼尼松超过2 g)。

核心结论

  • 2001年至2014年抗TNF药物使用增加,UC患者启动抗TNF前累积糖皮质激素使用显著下降,但CD患者无显著下降且免疫调节剂使用无变化。
  • 研究提示炎症性肠病患者抗TNF治疗仍需持续优化。

研究设计与样本

  • 基于马尼托巴大学炎症性肠病流行病学数据库的基于人群分析,识别2001年至2014年接受抗TNF治疗的CD和UC患者共950例(CD 761例,UC 189例)。
  • 评估不同时间段(2001年4月至2005年3月、2005年4月至2009年3月、2009年4月至2013年3月)抗TNF使用患病率和发病率的变化。
  • 主要终点为不同时间段首次接受抗TNF治疗的时间变化。

主要发现

  • 2014年当前或既往抗TNF暴露的累积患病率CD为20.4%,UC为6.0%。
  • 2014年诊断后5年内抗TNF暴露的累积发生率CD为23.4%,UC为7.8%。
  • 多数抗TNF使用者在启动治疗前存在糖皮质激素依赖(任意12个月内泼尼松超过2 g)的证据。
  • 抗TNF使用前累积糖皮质激素暴露在UC患者中随时间下降,但在CD患者中无显著下降。
  • 抗TNF治疗时联合免疫调节剂的使用随时间无增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Anti-tumor necrosis factor (anti-TNF) agents are effective treatments for Crohn's disease (CD) and ulcerative colitis (UC). We aimed to determine their patterns of use and changes in these patterns over time, as well as use of immunomodulators and corticosteroids before anti-TNF therapy for persons with inflammatory bowel diseases. METHODS: We used the University of Manitoba IBD Epidemiology Database to identify all anti-TNF users with CD and UC from 2001 through 2014. We assessed changes in the prevalence and incidence of anti-TNF use during different time periods (April 2001-March 2005, April 2005-March 2009, or April 2009-March 2013). We also characterized patterns of corticosteroid use, corticosteroid dependence, and immunomodulator use before anti-TNF administration and determined how these changed over time. The primary end point was change in time to first receipt of anti-TNF among the different time periods. RESULTS: We identified 950 persons (761 with CD and 189 with UC) who received anti-TNF agents. The cumulative prevalence of persons with current or prior anti-TNF exposure in 2014 was 20.4% for CD and 6.0% for UC. In 2014 the cumulative incidence values of anti-TNF exposure within 5 years of diagnosis were 23.4% for patients with CD and 7.8% for patients with UC. Most users of anti-TNF agents had evidence of corticosteroid dependence (more than 2 g prednisone within any 12-month period) before initiation of anti-TNF therapy. Cumulative corticosteroid exposure before anti-TNF use decreased over time for patients with UC, but not significantly for patients with CD. There was no increase over time in the use of concomitant immunomodulators with anti-TNF therapy. CONCLUSIONS: Use of anti-TNF agents increased from 2001 through 2014, with a concomitant significant decrease in cumulative use of corticosteroids before anti-TNF therapy for patients with UC. However, there has been no reduction in cumulative use of corticosteroids before anti-TNF therapy for patients with CD and no change in use of immunomodulators by patients with CD. These findings indicate a continuing need for optimization of anti-TNF therapy for patients with inflammatory bowel disease.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Targownik LE, Tennakoon A, Leung S, et al. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis. Clin Gastroenterol Hepatol. 2017. PMID: 28238957. doi:10.1016/j.cgh.2017.01.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。